Greenwich LifeSciences Provides Update on Corporate Events
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company developing GLSI-100 immunotherapy for breast cancer recurrence prevention, has provided an update on its corporate events calendar. The company has participated in multiple scientific meetings, healthcare conferences, and investment events throughout 2024, including the GBG Annual Scientific Meeting, ASCO Annual Meeting, BIO International Convention, and various healthcare investment conferences. Upcoming events include the Jefferies London Healthcare Conference, San Antonio Breast Cancer Symposium, Annual Meeting of Stockholders, and conferences extending into early 2025.
Greenwich LifeSciences (Nasdaq: GLSI), un'azienda biofarmaceutica in fase clinica che sviluppa GLSI-100 come immunoterapia per la prevenzione delle recidive del cancro al seno, ha fornito un aggiornamento sul suo calendario di eventi aziendali. L'azienda ha partecipato a numerosi incontri scientifici, conferenze sanitarie e eventi di investimento nel corso del 2024, tra cui il GBG Annual Scientific Meeting, l'ASCO Annual Meeting, il BIO International Convention e varie conferenze di investimento in sanità. Gli eventi futuri includono la Jefferies London Healthcare Conference, il San Antonio Breast Cancer Symposium, l'Annual Meeting of Stockholders e conferenze che si protrarranno fino all'inizio del 2025.
Greenwich LifeSciences (Nasdaq: GLSI), una empresa biofarmacéutica en etapa clínica que está desarrollando GLSI-100 como inmunoterapia para la prevención de la recurrencia del cáncer de mama, ha proporcionado una actualización sobre su calendario de eventos corporativos. La empresa ha participado en múltiples reuniones científicas, conferencias de salud y eventos de inversión a lo largo de 2024, incluyendo la Reunión Científica Anual de GBG, la Reunión Anual ASCO, la Convención Internacional BIO y varias conferencias de inversión en salud. Los próximos eventos incluyen la Conferencia de Salud de Jefferies en Londres, el Simposio sobre el Cáncer de Mama de San Antonio, la Reunión Anual de Accionistas y conferencias que se extenderán hasta principios de 2025.
그리니치 라이프사이언스(Greenwich LifeSciences, Nasdaq: GLSI)는 유방암 재발 방지를 위한 면역 치료제 GLSI-100를 개발 중인 임상 단계의 생명공학 회사로, 기업 이벤트 일정에 대한 업데이트를 제공했습니다. 이 회사는 2024년 동안 GBG 연례 과학 회의, ASCO 연례 회의, BIO 국제 대회 및 다양한 의료 투자 회의를 포함한 여러 과학 회의 및 건강 회의에 참여했습니다. 향후 행사로는 제퍼리즈 런던 헬스케어 컨퍼런스, 샌안토니오 유방암 심포지엄, 주주 연례 회의, 그리고 2025년 초까지 이어지는 여러 회의가 있습니다.
Greenwich LifeSciences (Nasdaq: GLSI), une entreprise biopharmaceutique en phase clinique développant GLSI-100 comme immunothérapie pour la prévention de la récidive du cancer du sein, a fourni une mise à jour de son calendrier d'événements d'entreprise. L'entreprise a participé à plusieurs réunions scientifiques, conférences de santé et événements d'investissement tout au long de 2024, y compris la Réunion Scientifique Annuelle de GBG, la Réunion Annuelle ASCO, la Convention Internationale BIO et diverses conférences d'investissement en santé. Les événements à venir comprennent la Conférence de Santé Jefferies de Londres, le Symposium sur le Cancer du Sein de San Antonio, la Réunion Annuelle des Actionnaires, ainsi que des conférences qui s'étendront jusqu'au début de 2025.
Greenwich LifeSciences (Nasdaq: GLSI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das GLSI-100 als Immuntherapie zur Prävention von Brustkrebsrückfällen entwickelt, hat ein Update zu seinem Unternehmensereigniskalender bereitgestellt. Das Unternehmen hat 2024 an mehreren wissenschaftlichen Tagungen, Gesundheitskonferenzen und Investitionsveranstaltungen teilgenommen, darunter das GBG Annual Scientific Meeting, das ASCO Annual Meeting, die BIO International Convention und verschiedene Gesundheitsinvestitionskonferenzen. Zu den bevorstehenden Veranstaltungen gehören die Jefferies London Healthcare Conference, das San Antonio Breast Cancer Symposium, die Jahreshauptversammlung der Aktionäre und Konferenzen, die bis Anfang 2025 andauern.
- None.
- None.
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on corporate events.
The Company's 2024 events to date are listed below:
- Feb 29 - Mar 1, 2024 – GBG Annual Scientific Meeting (German clinical network conference)
- Jun 1 - 4, 2024 – American Society of Clinical Oncology (ASCO) Annual Meeting
- Jun 3 - 6, 2024 – BIO International Convention (partnering conference)
- Jun 4 - 6, 2024 – Jefferies Global Healthcare Conference
- Sep 9 - 10, 2024 – H.C. Wainwright 26th Annual Global Investment Conference
- Oct 5, 2024 – Komen Houston Race for the Cure (sponsor)
- Nov 4 - 6, 2024 – 30th Annual BIO-Europe Fall 2024 (partnering conference)
- Nov 7, 2024 – 13th Annual Texas Life Science Forum (guest speaker)
The Company's planned upcoming events are listed below:
- Nov 19 - 21, 2024 – Jefferies London Healthcare Conference
- Dec 10 - 13, 2024 – San Antonio Breast Cancer Symposium (SABCS)
- Dec 19, 2024 – Annual Meeting of Stockholders
- Feb 10 - 11, 2025 – BIO CEO & Investor Conference
- Mar 6 - 7, 2025 – GBG Annual Scientific Meeting
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US clinical sites from university-based hospitals and cooperative networks with plans to expand into Europe and to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides
For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
FAQ
What conferences will Greenwich LifeSciences (GLSI) attend in December 2024?
What is GLSI-100 being developed for by Greenwich LifeSciences?
What major healthcare conferences did Greenwich LifeSciences (GLSI) attend in June 2024?
When is Greenwich LifeSciences (GLSI) scheduled to attend the BIO CEO & Investor Conference?
